

22ND ANNUAL

19-21 October, 2021

Palau de Congressos de Catalunya Barcelona, Spain

Research, Development and Strategic Partnering for the Global Vaccine Industry.





terrapinn.com/wvceu-2021prospectus


terrapinn.com/vetvax-prospectus2021

THE VACCINE INDUSTRY MEETING PLACE

The World Vaccine Congress is an award-winning series of conferences and an exhibition that has grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is shown through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.

Now in its 22nd annual, the World Vaccine Congress Europe, together with the co-located Veterinary Vaccine and Immuno-Oncology congresses, will continue to bring experts from the whole value chain under one roof, where you get to meet decision makers in the areas that are most applicable for your business offering. It will offer the chance to come together at a time where the disruption of COVID-19 has meant being able to network, learn and collaborate is as important as ever.

With 800+ potential customers in attendance there will be opportunities to find contacts who need to find solutions to challenges around the political, commercial and scientific issues in manufacturing, clinical trials, strategy, regulation, veterinary vaccines, immune profiling, AMR, respiratory, influenza, therapeutic and emerging diseases.



CONFERENCE THEMES



EVENT FEATURES:

COVID-19 HUB

A dedicated area for the latest updates and presentations from those leading the race and delivery of a vaccine.

WORLD LEADING PRESENTATIONS

Original presentations from the most informed Industry experts on COVID-19 and all vaccine related topics. Genuine leaders that you can learn from and take away tangible insights for your business.

THE STRONGEST AGENDA YET

Governed by our Scientific Advisory Board, which includes: 23 leading pioneers of the vaccine industry that have ensured the agenda, topics and speakers are relevant and cutting edge, so that your 3 days with us will be the most memorable yet.

INTERNATIONAL DECISON MAKERS

Hear from over 150+ senior speakers across the from the WHO, CEPI, European Commission, EMA, FDA in government to C-level executives from GSK, Merck, Pfizer, Janssen, Sanofi and innovative biotechs. This is your best chance of the year to meet and network with hundreds of like-minded peers at Europe's biggest vaccine meeting.

NEW WORKSHOPS, TRACKS AND TWO CO-LOCATED CONFERENCES

Attend focused sessions across multiple tracks AND two co-located congresses. Take this unique opportunity to gain not only the sessions at the World Vaccine congress, but also the 7th World Veterinary Vaccines Congress and 6th Immuno-Oncology Profiling World Congress.

PANEL DEBATES

We have curated panels of 4-5 industry experts to debate some of your burning questions. You'll be able to watch them live and pose questions directly the panelists.

NETWORKING

There are more networking opportunities, with three days' worth of content, extended breaks, multiple drinks receptions and two co-located events, you will have even more time to meet cross sector contacts with over 800 attendees.

OUR SCIENTIFIC ADVISORY BOARD

WORLDVACCINE WORLDVETERINARY IMMUNO ANCOLOGY





Dr Ofer Levy Harvard Medical School

Dr Miles Carroll Public Health England

Dr Gregory Poland Mayo Clinic

Dr Nathalie

Garcon

Bioaster



Dr Cyril Gay

USDA

Dr Annaliesa Anderson Pfizer



Prof Hanneke Schuitemaker Janssen

Prof Albert Osterhaus **RIZ**, Hannover University

Prof Jeffrey Almond University of Oxford

Dr Bruce Gellin

Sabin Vaccine

Institute

Dr Maria Elena

Bottazzi

Baylor College of

Medicine & Texas Children's Hospital Dr Jan Poolman Janssen

Dr Jerald Sadoff Janssen

Dr Antu Dey IAVI

Dr Rino

Rappuoli

GSK





Dr Konrad Stradler CEVA





Former OiE

Dr Roy Baynes

MSD

Dr Mahesh Kuman Zoetis



Dr Ralf Clemens GRID Rio



Prof Fred Zepp Dr Joris University of Mainz Vandeputte IABS

Dr Gregory

Glenn

Novavax

Dr Lorne Babiuk University of Alberta





Prof Stanley

Plotkin

Vaxconsult & University of Pennsylvania School of Medicine



Prof Bali Pulendran

Stanford University

Prof Heidi

LSHTM

IVI





Prof Helen McShane University of Oxford

Dr Walter Straus

MSD

OICR

Dr Peter Hotez

Dr Christiane Gerke **Baylor** College of Medicine & Texas Institute Pasteur Children's Hospital

Dr Leonard Friedland GSK

Dr Roman Chicz

Sanofi

Prof Mark Davis Stanford University



The Children's Hospital of Philadelphia



Larson















Dr George Siber



TOPICS

Multifaceted technology platforms De-risked animal models Immune characterisation Interplay with T/B cells Vaccine & antibody Design



Technology & delivery platforms Companion animal therapeutics Adjuvants, mAbs, stem cells Cross species technologies Therapeutic applicability Cancer vaccines Animal models

WORLDVACCINE

EUROPE



COVID vaccines Transboundary diseases Antimicrobial resistance Autogenous vaccines **Clinical models** Technology Adjuvants Regulation One Health Disease X



BARCELONA AGENDA OVERVIEW Oct 19, 2021

Oct 19 Day 1 CET			KE	YNOTES		
9:00 - 9:30	•				programm	e – from strategy to delivery
9:00 - 9:30	 Dr Jonathan Van Tam, Deputy Chief Medical Officer, England Keynote panel: Efficacy data from COVID vaccines and preparedness for variants Global vaccine effectiveness rates: Are effectiveness data supporting the efficacy from clinical trials? What is being seen in vaccine effectiveness data and impact across products and across populations? How will the different vaccines interact in the immune system? Can we mix & match and is that safe? Does prevention of transmission and protection against mild disease really matter? Are we prepared for variants? Dr Kate O'Brien, Director of Vaccines, WHO Dr Matthew Snape, Professor in Paediactrics & Vaccinology, University of Oxford Dr Randall Hyer, Head of Medical Affairs, Moderna Dr Hanneke Schuitemaker, VP, Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines Dr Rino Rappuoli, Chief Scientist, GSK Vaccines 					
10:30 - 11:00	Dr Prakash Bhuyan, MD, Vice President, Head of Infectious Diseases, Clinical Development, AstraZeneca 0:20 – 11:00 Expo & Partnering Morning Break					
11:00 – 12:00	Regulatory safety in vaccines - Title TBC Senior representtive, SGS Patents and the role of big pharma in and	pr upco	e we ready and epared for the oming flu season?	ive roundtable Deploym procurement vaccir	ent & of COVID	Next generation vaccines – what will these look like and with what technology? Currently accepting roundtables
	manufacturers during a pandemic – has a new model been built from this experience?	Seni	ndtable title TBC or representtive, Health Sciences			Contact <u>Wing-</u> yun.Cheung@Terrapinn.com or Nadia.Konneh@Terrapinn.com
12:00 - 13:30			Expo & Part	nering Lunch I	Break	
Tracks	COVID-19		Clinical Deve	lopment		Immune Profiling
Afternoon Sessions	13:30 – 14:30 Panel: How coronavirus evolve as it establishes itself in the human population? Flu- Rhino-like or measles-lik Professor Jeffrey W. Alm PhD. FMedSci. Visiting Professor of Microbiolog University of Oxford	like, ce? nond	13:30 Use of neut studies to monito immunisation stra Dr Nick Gent, Seni Adviser (Emergend Department), PHE 13:45 Animal Stu Reproducibility: P Solutions	r and inform ategies ior Medical cy Response	endotype: disease in - Transcr signatu progno - Progno	atures for distinct disease s and progression to active tuberculosis "iptomic and metabolomic res that allow diagnosis and sis of tuberculosis stic markers of progression to disease will pave the way to

	Dr Sharon Peacock, Executive Director, COVID-19 Genomics UK (COG-UK) consortium Dr Helena Maier, Group Leader, Coronaviruses, Pirbright	Systems, Inc.	biomarkers which can predict vaccine efficacy Professor Stefan Kaufmann, Director Emeritus, Immunology, Max Planck Institute for Infection Biology 14:00 Using systems vaccinology/ biology to understand host responses to childhood vaccinations Daniel O'Connor, University Research Lecturer, Senior Bioinformatician, Oxford Vaccine Group
	14:30 UK's data and interpretation from COVID-19 variants Dr Alessandro Carabelli, COVID-19 Genomics UK (COG- UK) consortium	Preparation for Disease X – final title TBC	14:30 A modern approach to traditional virology research Reserved for Nexcelom 14:45 Accelerating the next generation of immune medicine with functional phenotyping - <i>title tbc</i> Reserved for IsoPlexis
	15:00 Rapid development to automated scale: Agile response to support SARS- CoV-2 vaccines and therapeutics Dr Luc Gagnon, Vice President, Vaccine Sciences, Nexelis	15:00 Antimicrobial resstance – title TBC Shelley McLendon, Vice President, Vaccine and Infectious Disease, ICON & Caroline Forkin, Vice President, Global Research Services, Government and Public Health Solutions, ICON	 15:00 Combining single cell transcriptomics with antibody repertoire sequencing, in order to map the germinal centre response in fine detail Investigating the human immune system with the tonsil as a model to understand normal immune process Dr Louisa James, Lecturer in Immunology, Blizard Institute, Queen Mary University of London 15:15 STriTuVaD simulation platform: A computational platform to predict the effects of vaccines Invited: Prof Francesco Pappalardo, Scientific Coordinator, STriTuVaD project
Afternoon break		15:30 – 16:00 Expo & Partneri	ing Break
Afternoon Sessions	16:00 Risk Assessment of SARS-CoV-2 variants of interest and impact on vaccine escape Dr Bassam Hallis, Head of Pre- Clinical Dev & General Project Manager, National Infection Service, Public Health England	16:00 The future of vaccine clinical trials in the post-COVID era Martina Kovac, M.D., Vice President, Global Product Development, Vaccines, PPD	Adjuvants 16:00 Next generation saponin adjuvant: First-in-human clinical trial results Dr Tyler Martin, CEO, Adjuvance Technologies

16:30 Comparing COVID-19 vaccine schedule combinations - Com-COV2 study findings so far Dr Matthew Snape, Professor in Paediactrics & Vaccinology, University of Oxford	16:30 Control potential viral contaminants in vaccines and biologics with effective testing Margaret Temple, Business Development Director, SGS	16:15 Co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines
16:45 <i>Reserved</i>		16:30 Panel: What will the role of adjuvants be in future pandemic preparedness? Panellists to be announced
17:00 – 17:15 Development of a multiplexed and high- throughput SARS-CoV-2 serology assay Dr Gemma Moncunill, Assistant Research Professor, IS Global 17:30 <i>Title TBC</i> Senior representative, Sartorius	17:00 Successful execution of a Phase 3 COVID-19 vaccine clinical trial – <i>final title TBC</i> Senior representative, Accelerated Enrollment Solutions (AES) 17:30 <i>Reserved</i>	
	18:00 Sponsored Evening Netwo End of day 1	rking Drinks

Oct 20, 2021

Oct 2 Day		KEYNOTES			
 08:00 – 09:00 Keynote: Impact of mRNA vaccines and new generation of vaccines for th What is the future for mRNA vaccines for future pandemics, existing infectious discancer? Will RNA vaccines be accessible and sustainably produced for worldwide use? Dr Andreas Kuhn, Senior Vice President RNA Biochemistry & Manufacturing, BioNtech David Hering, Global mRNA Business & Franchise Lead, Pfizer Kumaran Vadivelu, Vice President, Vaccine Development Team Leader, GSK Vaccines Invited: Moderna Morning plenary 09:00 – 10:00 Keynote: Should we be vaccinating children with the new COVID vaccine: our strategy with other population/age groups? What do we know about paediatric & maternal immunisation with these new vac What risk does SARS-Cov-2 pose to the new-born? Strategy and vaccine considerations to vulnerable groups Dr Gregory Glenn, President R&D, Novavax Dr Randall Hyer, Head of Medical Affairs, Moderna Prof Carl S. Goodyear, Director of GLAZgo Discovery Centre, Senior Senate Assessor on C Professor of Translational Immunology, Institute of Infection, Immunity and Inflammation Medical, Veterinary and Life Sciences, University of Glasgow 			infectious diseases and vide use? g, BioNtech C Vaccines OVID vaccines & what is nese new vaccines?		
Morning	break	k 10:00 – 10:30 Expo & Partnering Break			
Tracks		One Health	AMR & Bacterial Vaccines Chair: Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen	Bioprocess & Manufacturing	Respiratory Diseases
Afternoor Sessions	as a m vaccin produ Mode Vande IABS Jean-C Audor Direct Ingelh & Coo Projec Dr Elis Vinde Antim and Ve Depar Prof A Direct For En	andel for surge the development and ction rator: Joris eputte, President, Christophe anet, Senior or, Boehringer eim Animal Health rdinator of ZAPI IMI	role of vaccines Dr Isabel Frost, Consultant, Vaccines and AMR, WHO 11:00 – 12:00 CARB-X supported companies and pipeline updates <i>Moderated by</i> Ed Buurman,	10:45 Large-scale production of subunit vaccines in a bioreactor- free system Dr Jose Escribano, CSO, Algenex Expediting Viral-Based Vaccines Development in a Pandemic Situation -	 10:30 - 11:30 Panel: Clinical development learnings from COVID-19 Correlatesof protection Heterologous priming and boosting strategies Variant-adapted vaccines Planning Phase 3 ahead, country selection etc. Safety signals popping up during vaccine roll out phase, communication strategies Regulatory lessons learned

University of Veterinary Medicine Hannover	Dr Calman MacLennan, Professor of Vaccine		<i>Moderator:</i> Dr Jakob Cramer, Head of Clinical
Stig Tollefsen , Technology Office Lead, CEPI	Immunology, Jenner Institute		Development , CEPI
	- Kleb-Acinteo-Pseudo		Dr Matthew Snape, Professor in Paediactrics 8
	Dr Juanjo Infante, CEO, Vaxdyn		Vaccinology , University o
			Oxford
			Invited speakers: Dr Peter Dull, Deputy
			Director, Integrated
			Clinical Vaccine
			Development, Bill &
			Melinda Gate Foundatio
			Dr Lidia Oostvogels,
			CureVac - TBC
			Dr Robert Chen, Scientific
			Director, Brighton
			Collaboration - TBC
			Dr Marco Cavaleri, Head
			of Office, Anti-infective
			and Vaccines in the
			Human, Medicines
			Evaluation Division, EMA TBC
11:30 Tackling		11:30 Biomanufacturing	11.20 India's COVID
coronaviruses with cross-		technology advances for	
reactive monoclonal		accelerated and	
antibodies		decentralized vaccine	
Dr Berend Jan Bosch,		manufacturing (COVID19	
Faculty of Veterinary Medicine, Utrecht		case study) Senior representative,	
University		Univercells	
		11:45 An enzymatic	11:45 COVAC-2: a S1
		nucleic acid vaccine	subunit-based COVID-19
		platform optimised for	vaccine adjuvanted with
		global pandemic	Sepivac SWE™
		response	Trina Racine, Associate
		Dr Jill Makin, Chief Technology Officer	Director, Vaccine
		Dr Jill Makin, Chief Technology Officer, Touchlight	Director, Vaccine Development, VIDO
		Technology Officer,	
		Technology Officer,	

12:00 Epidemiology of bacteremia and sepsis

12:00 Vaccine processing, 12:00 Trial update on manufacturing strategies Novavax's COVID vaccine

	12:00 Combatting Nipah Virus: Developing a vaccine for pigs Dr Dalan Bailey, Group Leader, Cell Biology, Innate Immunity, Molecular Virology, Proteomics, Viral Diseases, The Pirbright Institute	Dr Thomas Verstraeten, CEO, P-95 12:15 E.coli vaccines Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen	to accelerate Innovation & speed Jérome Dalin, EMEA Core Modalities Strategy operationalization – Senior Consultant – Bioprocessing, Merck KGaA	Dr Gregory Glenn, President R&D , Novavax
Lunch Break		12:30 – 14:00 Expo &	Partnering Break	
	14:00 – 15:00 Panel: Novel approaches to human and animal vaccine development <i>Moderator</i> : Dr Vish Nene, Co-leader Animal and	14:00 Presentation: TB 14:15 Presentation: Staph	Presentation title TBC Senior representative, Kuhner Shaker Modified vaccinia virus ankara: Platform based development and	14:00 COVID vaccine update Dr Hanneke Schuitemaker, VP, Viral Vaccine Discovery and Translational Medicine,
	Human Health program, International Livestock Research Institute Dr Neil King, Assistant Professor, The Institute for	aureus	manufacturing Dr Simone Kardinahl, Vice President Development, IDT Biologika Reserved: ultraDAWN:	Janssen Vaccines 14:30 Are we ready and
	Protein Design, University of Washington Prof John Hammond, Group Leader, Genetics, Genomics, Immunology, The Pirbright Institute Fred Fellouse, Senior		real-time DSP analytics using light scattering Dr Dan Some, Principal Scientist, Wyatt Technology Corp. 14:45 COVID case studies:	prepared for the upcoming flu season? Lyn Morgan Marsden, Senior Director Public Affairs, Sanofi & IFPMA Vaccines Committee Chair
	Research Associate, The Donnelly Centre , University of Toronto	Panel: How do we assess	Process development and fixed based reactors - TBC Senior representative, Batavia Biosciences Bioprocessing challenges	
	15:00 Rift valley fever: Developing the world's first vaccine suitable for humans and livestock Invited: George Warimwe, Group Leader, KEMRI- Wellcome Trust Research Programme, Kenya; Associate Professor, Centre for Tropical Medicine & Global Health, University of Oxford	Panel: How do we assess the value of vaccine preventable AMR diseases? - Antibiotic awareness - Future strategy to protect the aging population and pneumococcal vaccinations - How do we assess value? - Economic and public health burden of AMR Moderator:	Bioprocessing challenges of adjuvanted vaccine development Dr Charles Lutsch, AVP R&D Enabling Sciences & Head Adjuvant Center, Sanofi Pasteur Increasing vaccine production using Viral Sensitizer Technology Reserved for Dr Jean- Simon Diallo, CEO & Scientific Founder, Virica Biotech Inc	vaccines

	15:30 Large animal	Dr Jan Poolman, Head	15:30 – 16:30 Panel: How	15.30 BSV vaccines
	challenge models for	Bacterial Vaccine Discovery	will we better deliver	13.30 NSV Vaccines
	assessment of human and	· · · · · · · · · · · · · · · · · · ·	more sustainable vaccine	Reserved for Icosavax
	veterinary negative	Janssen	manufacturing during	
	strand virus recombinant		outbreaks?	
	vaccines	Agopsowicz, Technical	- How to establish	
		Officer & Project Manager,		
		Vaccine Product & Delivery	regional health security	
		Research	- The need to develop a	
		Immunization, Vaccines and	long-term	
		Biologicals (IVB), WHO	manaractaring road	
		Dr Anthony Fiore, MD,	map	
			- Identifying	
		MPH, Chief, Epidemiology	manufacturing capacity	
		Research and Innovations	and capability	
		Branch, Division of	Madavatary Davida	15:45 RSV vaccines
		Healthcare Quality	in ouclator. I daid	
		Promotion, NCEZID, CDC	Barbosa,	
		,	Associate Director,	
		Vaccines, Wellcome Trust	Vaccine Policy, IFPMA	
			Dr Matthew Downham,	
			Sustainable	
			Manufacturing Lead, CEPI	
			Matthew Duchars, CEO,	
			The Vaccines	
			Manufacturing &	
			Innovation Centre	
			Martin Friede,	
			Coordinator, Initiative for	
			Vaccine Research (IVR),	
			WHO	
			Vivian Hsu, Deputy	
			Director Strategy Planning	
			and Management,	
			Vaccine Development &	
			Surveillance, BMGF	
Break		16:00 – 16:30 Afternoon		
		KEYNOTI	E	
Closing		el – how can we better colla	aborate with a one health a	approach to prepare for
Plenary	the next pandemic?			
		bathogens likely to be?		
		tory? Arthropod borne? Fae	co-oral? Sexually transmitte	ed? Or antibiotic resistant
	bacteria?			
		al vaccines for groups of viru		threaks
		shot timeline achievable for f		
		d of Section Support/Group I		gency operations,
		se Prevention and Control (I		Drotoomics Viral Dissess
		ider, Cell Biology, Innate Imm	iunity, wolecular virology,	Proteomics, viral Diseases,
	The Pirbright Institute			
	Senior representative, WH			
	Senior representative, CEP			
		18:00 Sponsored Eveni		
		End of	day 2	

Oct 21, 2021

DEDICATED TRACK SESSIONS

Oct 21 Day 3		DEDICATED TRACK SESSIONS	5
9:00 – 9:30	Morning Networking		
Tracks	Emerging Disease X	Immuno-Oncology Profiling	Logistics, Delivery & Access
	 09:30 – 10:30 What's on our priority pathogens list? Progress on Chik, Nipah, Lassa, Ebola Investing in research early for non commercial vaccines Building a sustainable 	09:30 SARS-CoV-2 vaccines and cancer patients Dr Giuseppe Curigliano, Director, New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology	09:30 Decentralized trials: How to develop a flexible supply chain strategy – Title TBC Senior represenative, Marken
	prepardness model Senior representative, WHO More panellists TBC	10:00 How to match tumour mutanomes to improve immune responses Prof Wim Van Criekinge, CSO, myNEO	10:00 Presentation – Title TBC David Hipkiss, CEO, Enesi Pharma 10:15 Progress of COVID-19 vaccines with needle-free delivery Erin Spiegel, VP of Clinical and Regulatory Affairs, Pharmajet
	10:30 Vaxchora [®] (Cholera Vaccine, live, oral) in Children and Adolescents – A Review Dr Mark Schneider, Sr. Director, Global Medical Affairs - Vaccines and Therapeutics, Emergent Biosolutions 11:00 Progress with malaria vaccination Dr Adrian Hill, Professor, University of Oxford	 10:30 Panel: Early-stage immuno- oncology clinical trials and the importance of understanding mechanisms in human subjects Discussing deficiencies in preclinical models Exploring how newer technologies are powering translational medicine Designing early-stage studies to maximise the chances of success Moderator: Dr Philip Beer, Physician Scientist And Precision Oncology Specialist, Sanger Institute Dr Giuseppe Curigliano, Director, New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology Katja Rybakova, Founder, Cellgebra & Senior Researcher, Royal College of Surgeons Ireland 	 Delivery with good ordinary cold chain stability and balanced Th1 / Th2 immunogenicity Formed with bio-degradable materials with clean GLP profile Jason Huang, CMO, Ascendo Biotech

Break	11:30	0 – 12:30 Expo & Partnering Brunch	Break
	12:30 – 13:30 Panel: Is it feasible to develop universal/pan corona	Therapeutic Vaccines	12:30 – 13:30 Panel: Strengthening immunization
	to develop universal/pan corona vaccines? Moderator: Dr Maria Elena Bottazzi, Associate Dean, National School of Tropical Medicine & Co- Section Head, Pediatric Tropical Medicine Prof Ab Osterhaus, Director, Research Center For Emerging Infections And Zoonoses (Riz), University of Veterinary Medicine Hannover Ronald Kempers, Mymetics – invited More panellists to be announced	12:30 Update on Vaccitech's therapeutic hepatitis B program Dr Thomas Evans, CSO & Board Director, Vaccitech 12:50 Progress in combination immunotherapy of cancer involving therapeutic vaccination Cornelis Melief, Chief Scientific Officer, ISA Pharmaceuticals 13:10 Developing personalized neoantigen cancer vaccines to target solid tumors Agnete B. Fredriksen, Chief Innovation & Strategy Officer, Vaccibody AS	Strengthening immunization programs and recovering routine immunization rates Vaccine alliances, policy and access Risks of measles and other vaccine-preventable disease outbreaks re-emerging as a result of un/under-vaccination during the pandemic Addressing various factors, such as public discomfort in accessing the healthcare system for fear of contracting COVID, disruptions to immunization programs, diversion of staff/resources, etc. Dr Julia Spencer, Associate Vice President, Global Public Policy, MSD Jean-Cédric Meeùs, Chief Transport, UNICEF Supply Division Ingrid Keller, European Commission, Acting Head Chronic Disease and Health Programme Unit, DG Health and Food Safety
	13:30 Presentation	13:30 – 14:30 How do we build a	More panellists to be announced 13:30 – 14:30 Panel: Insights on
	14:00 Presentation	 better, more successful immuno- oncology clinical development paradigm? Obstacles in current IO drug & therapeutic development Discussing how the immuno- oncology field has hit an asymptote in therapeutic gains using the current models of cancer drug development How can we improve the immuno-oncology drug development pipeline by using earlier stage nimble trials? Moderator: Dr Laszlo Radvanyi, President and Scientific Director, Ontario Institute for Cancer Research 	how to implement new partnership models for international collaboration among vaccine manufacturers, NGOs and government - How do we continue to pursue International collaborative research and partnering opportunities for vaccine development? - What gaps and other challenges do we still face in order to deliver enough COVID vaccines globally? Professor Jeffrey W. Almond PhD. FMedSci. Visiting Professor of Microbiology, University of Oxford

Break	14:30 – 15:00 Expo & Partnering Afternoo	Transport, UNICEF Supply Division Dr Maria Elena Bottazzi, Associate Dean, National School of Tropical Medicine & Co-Section Head, Pediatric Tropical Medicine Neil Jones, Chief Business Officer, The Vaccines Manufacturing & Innovation Centre More panellists to be announced n Break	
Closing Plenary Di Di Lis Isa	When will the majority of the population be vaccinated and protected from COVID? When will the majority of the population be vaccinated and protected from COVID? What hurdles do we face that could prevent us from achieving our goals? Why are there such differences between countries? Has vaccine distribution been fair? Tackling misinformation The impact of the pandemic on routine immunization programs		



EVENT TEAM

SPEAKING OPPORTUNITIES

Wing-Yun Cheung wing-yun.cheung@terrapinn.com

Nadia Konneh nadia.konneh@terrapinn.com

SPONSORSHIP & EXHIBITION

Marc Rhys- Evans marc.rhys-evans@terrapinn.com

Oliver Breed oliver.breed@terrapinn.com

MARKETING OPPORTUNITIES

Karina Kusova Karina.kusova@terrapinn.com